Skip to Content

Dr Reddy's Laboratories Ltd 500124

Morningstar Rating
INR 6,253.25 +36.10 (0.58%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

500124 is trading within a range we consider fairly valued.
Price
INR 6,008.45
Fair Value
INR 7,871.96
Uncertainty
High
1-Star Price
INR 8,365.83
5-Star Price
INR 3,988.15
Economic Moat
Hfgm
Capital Allocation
Jcqqwsgw
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 500124 is a good fit for your portfolio.

News

Trading Information

Previous Close Price
INR 6,217.15
Day Range
INR 6,181.706,310.00
52-Week Range
INR 4,383.406,505.50
Bid/Ask
INR 0.00 / INR 0.00
Market Cap
INR 1.04 Tril
Volume/Avg
8,637 / 13,173

Key Statistics

Price/Earnings (Normalized)
19.40
Price/Sales
3.65
Dividend Yield (Trailing)
0.64%
Dividend Yield (Forward)
0.64%
Total Yield
0.64%

Company Profile

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Core
Total Number of Employees
22,822

Competitors

Valuation

Metric
500124
NVS
TEVA
Price/Earnings (Normalized)
19.4014.124.99
Price/Book Value
3.725.011.91
Price/Sales
3.654.050.90
Price/Cash Flow
14.9013.449.93
Price/Earnings
500124
NVS
TEVA

Financial Strength

Metric
500124
NVS
TEVA
Quick Ratio
1.800.610.54
Current Ratio
2.550.901.02
Interest Coverage
46.5211.320.39
Quick Ratio
500124
NVS
TEVA

Profitability

Metric
500124
NVS
TEVA
Return on Assets (Normalized)
15.57%13.39%6.70%
Return on Equity (Normalized)
21.70%31.09%39.00%
Return on Invested Capital (Normalized)
20.10%19.67%13.54%
Return on Assets
500124
NVS
TEVA
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class ALfgnnhpzfTbr$72.4 Bil
MKKGY
Merck KGaA ADRJnnmzjtvTrvxgt$70.8 Bil
HLN
Haleon PLC ADRYmxbypmgwSdlf$38.2 Bil
VTRS
Viatris IncZryypkglDjb$13.6 Bil
RDY
Dr Reddy's Laboratories Ltd ADRHjjhzygVchc$12.5 Bil
CTLT
Catalent IncSjptndhnDtkwx$10.1 Bil
PRGO
Perrigo Co PLCTzvdpkmqJdnq$4.3 Bil
CURLF
Curaleaf Holdings IncCkhqhdzkwVvdj$3.7 Bil
PBH
Prestige Consumer Healthcare IncRhhjgtmjwTvrrztk$3.5 Bil
GTBIF
Green Thumb Industries IncMyvtsfzxrNqbd$2.9 Bil

Sponsor Center